Global Allergy Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type (Eye Allergy, Food Allergy, Skin Allergy, Asthma, Rhinitis, Others), By Treatment (Anti-Allergy Medications v/s Immunotherapy), By Route of Administration (Oral, Inhalers, Intranasal, Others), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacie

According to a report published by Food Allergy Research & Education in 2020, estimated that around 32 million residents in the United States have food allergies.

Rising Pollution Levels

Increasing indoor and outdoor pollution is leading to an increase in prevalence of asthma and different allergic disorders of the respiratory tract. In 2019, around 7.8% population in the United States had asthma. This in turn is expected to spur the market growth through 2027. Additionally, air pollution can aggravate the symptoms of allergic rhinitis such as headaches, blocked or runny noses, itchy or watery eyes and sleep disturbances. Also, studies suggest that different eye allergies can be caused due to presence of different pollutants in indoor and outdoor air. This in turn is expected to increase the demand for treatments specific to the allergies caused due to pollution.

Development of Immunotherapies for Treatment of Allergies

According, to clinicaltrials.gov, as of September 2022 there are around 364 allergy immunotherapy studies under different phases of development worldwide.

Download Free Sample Report

Market Segmentation

Market Players

Johnson & Johnson, Sanofi SA, GlaxoSmithKline plc., F. Hoffmann-La Roche AG, Leti Pharma GmbH, AbbVie Inc., Alembic Pharmaceuticals Limited, Bausch Health Companies Inc., Novartis AG, ALK-Abello AS